SG11201401658SA - Functionalized nanoparticles for intracellular delivery of biologically active molecules - Google Patents

Functionalized nanoparticles for intracellular delivery of biologically active molecules

Info

Publication number
SG11201401658SA
SG11201401658SA SG11201401658SA SG11201401658SA SG11201401658SA SG 11201401658S A SG11201401658S A SG 11201401658SA SG 11201401658S A SG11201401658S A SG 11201401658SA SG 11201401658S A SG11201401658S A SG 11201401658SA SG 11201401658S A SG11201401658S A SG 11201401658SA
Authority
SG
Singapore
Prior art keywords
biologically active
active molecules
intracellular delivery
functionalized nanoparticles
functionalized
Prior art date
Application number
SG11201401658SA
Inventor
Andranik Andrew Aprikyan
Kilian Dill
Original Assignee
Stemgenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemgenics Inc filed Critical Stemgenics Inc
Publication of SG11201401658SA publication Critical patent/SG11201401658SA/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/34—Belt retractors, e.g. reels
    • B60R22/341—Belt retractors, e.g. reels comprising energy-absorbing means
    • B60R22/3413—Belt retractors, e.g. reels comprising energy-absorbing means operating between belt reel and retractor frame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
    • B60R2022/286—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices using deformation of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
    • B60R2022/289—Energy-absorption curves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
SG11201401658SA 2011-10-21 2012-10-22 Functionalized nanoparticles for intracellular delivery of biologically active molecules SG11201401658SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550213P 2011-10-21 2011-10-21
PCT/US2012/061391 WO2013059831A1 (en) 2011-10-21 2012-10-22 Functionalized nanoparticles for intracellular delivery of biologically active molecules

Publications (1)

Publication Number Publication Date
SG11201401658SA true SG11201401658SA (en) 2014-07-30

Family

ID=48141479

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601746TA SG10201601746TA (en) 2011-10-21 2012-10-22 Functionalized nanoparticles for intracellular delivery of biologically active molecules
SG11201401658SA SG11201401658SA (en) 2011-10-21 2012-10-22 Functionalized nanoparticles for intracellular delivery of biologically active molecules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201601746TA SG10201601746TA (en) 2011-10-21 2012-10-22 Functionalized nanoparticles for intracellular delivery of biologically active molecules

Country Status (14)

Country Link
US (1) US9675708B2 (en)
EP (2) EP3400956A1 (en)
JP (3) JP2014532628A (en)
KR (3) KR20200040924A (en)
CN (2) CN104094119A (en)
AU (3) AU2012325723A1 (en)
BR (1) BR112014009753B1 (en)
CA (2) CA2938661A1 (en)
HK (1) HK1201089A1 (en)
IN (1) IN2014DN03224A (en)
MX (3) MX2014004778A (en)
RU (2) RU2018135567A (en)
SG (2) SG10201601746TA (en)
WO (1) WO2013059831A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012325723A1 (en) * 2011-10-21 2014-05-15 Stemgenics, Inc Functionalized nanoparticles for intracellular delivery of biologically active molecules
EP3673913A1 (en) 2013-03-01 2020-07-01 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
HUE046924T2 (en) * 2013-03-01 2020-03-30 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US10100332B2 (en) 2013-08-23 2018-10-16 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
US11306326B2 (en) 2013-08-23 2022-04-19 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
EP3105318A1 (en) * 2014-02-10 2016-12-21 Nvigen, Inc. Cell modulation nanocomposition, and methods of use
CN105440112A (en) * 2015-12-07 2016-03-30 国家纳米科学中心 Polypeptide-albumin coupling drug and preparing method and application thereof
KR20190028665A (en) * 2016-06-03 2019-03-19 스템제닉스 인코포레이티드 Direct reprogramming of human somatic cells to selected (predetermined) differentiated cells using functionalized nanoparticles
US20210154323A1 (en) * 2016-06-03 2021-05-27 Stemgenics, Inc. Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use
US20190233820A1 (en) * 2016-10-11 2019-08-01 Stemgenics, Inc. Nanoparticles functionalized with gene editing tools and related methods
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
WO2018226529A1 (en) * 2017-06-05 2018-12-13 The Regents Of The University Of Michigan Complexes for delivery of antigenic peptides
CN108287235B (en) * 2018-02-07 2021-03-09 常州天地人和生物科技有限公司 Preparation and application of efficient and stable magnetic immune microspheres
US20200326325A1 (en) 2019-04-12 2020-10-15 Lisa Diamond Nanosensor chip with compound nanopores
CN110642876A (en) * 2019-10-10 2020-01-03 南京市口腔医院 Cysteine modified gold nanoparticles, preparation method and application thereof, and product for promoting bone tissue regeneration
CN112472685B (en) * 2020-12-10 2023-03-24 哈尔滨工业大学 Preparation method of hybrid neutrophil granulocytes robot

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767635B1 (en) * 1999-09-14 2004-07-27 Biomedical Apherese Systeme Gmbh Magnetic nanoparticles having biochemical activity, method for the production thereof and their use
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
CN101389314A (en) * 2005-03-14 2009-03-18 得克萨斯大学体系董事会 Bioactive fus1 peptides and nanoparticle-polypeptide complexes
EP1957045A2 (en) * 2005-03-14 2008-08-20 Board of Regents, The University of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
CA2611985C (en) * 2005-06-17 2016-08-16 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
EP2099496A2 (en) * 2006-12-08 2009-09-16 Massachusetts Institute of Technology Delivery of nanoparticles and/or agents to cells
CA2672998C (en) 2007-01-02 2013-08-06 University Of Central Florida Research Foundation, Inc. Methods and materials for stimulating proliferation of stem cells
KR100925689B1 (en) * 2007-07-25 2009-11-10 한국생명공학연구원 Multifunctional Protein Simultaneous Delivering Antibodies and Nanoparticles
WO2009035541A1 (en) 2007-09-10 2009-03-19 Merck & Co., Inc. Method of treating inherited severe neutropenia
KR100951719B1 (en) * 2007-10-02 2010-04-07 재단법인서울대학교산학협력재단 Complex of Cell Translocational Peptide and Magnetic Nanoparticulates and Use Thereof
US20110190729A1 (en) * 2007-11-30 2011-08-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
AU2009215426B2 (en) * 2008-02-21 2015-06-11 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with C-terminal elements
CA2748009A1 (en) * 2008-12-23 2010-07-01 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
TWI576432B (en) * 2009-04-07 2017-04-01 陶氏農業科學公司 Nanoparticle mediated delivery of sequence specific nucleases
AU2012325723A1 (en) * 2011-10-21 2014-05-15 Stemgenics, Inc Functionalized nanoparticles for intracellular delivery of biologically active molecules

Also Published As

Publication number Publication date
AU2020223737A1 (en) 2020-09-17
BR112014009753B1 (en) 2020-09-15
RU2014120465A (en) 2015-11-27
HK1201089A1 (en) 2015-08-21
US9675708B2 (en) 2017-06-13
JP2017165781A (en) 2017-09-21
AU2018203848A1 (en) 2018-06-21
MX2014004778A (en) 2014-10-17
CA2938661A1 (en) 2013-04-25
IN2014DN03224A (en) 2015-05-22
KR20150001711A (en) 2015-01-06
JP6560302B2 (en) 2019-08-14
CN106822868A (en) 2017-06-13
MX2018010696A (en) 2020-09-02
AU2012325723A1 (en) 2014-05-15
JP2014532628A (en) 2014-12-08
WO2013059831A1 (en) 2013-04-25
KR20190077124A (en) 2019-07-02
CN104094119A (en) 2014-10-08
RU2018135567A (en) 2018-11-15
EP2769217A4 (en) 2015-06-03
US20140342004A1 (en) 2014-11-20
MX367656B (en) 2019-08-29
JP2018184485A (en) 2018-11-22
KR20200040924A (en) 2020-04-20
CA2853128C (en) 2016-09-27
BR112014009753A2 (en) 2017-04-25
EP2769217A1 (en) 2014-08-27
CA2853128A1 (en) 2013-04-25
EP3400956A1 (en) 2018-11-14
SG10201601746TA (en) 2016-04-28

Similar Documents

Publication Publication Date Title
HK1201089A1 (en) Functionalized nanoparticles for intracellular delivery of biologically active molecules
SG11201501951YA (en) Branched polyamines for delivery of biologically active materials
IL229041B (en) Intravascular delivery of nanoparticle composiitons and uses thereof
EP2790736A4 (en) In vivo delivery of oligonucleotides
EP2788439A4 (en) Device having titania nanotube membrane for drug delivery
EP2768942A4 (en) Intracellular delivery
SG10201605537XA (en) Liposomes having useful n:p ratio for delivery of rna molecules
SG10201508662SA (en) Methods for drug delivery
GB201121070D0 (en) composition for delivery of biotherapeutics
BR112013028570A2 (en) polymeric nanoparticles for drug delivery
EP2741775A4 (en) Polymeric nanoparticles for photosensitizers
EP2765996A4 (en) Nanoparticles for controlling bleeding and drug delivery
GB201308796D0 (en) Customisation of mobile-application delivery
EP2544768A4 (en) Anti-cancer agent delivery vehicles capable of improved laoding
EP2665431C0 (en) Drug delivery technology
EP2794879A4 (en) Compositions and methods for the delivery of biologically active rnas
HRP20181316T1 (en) Drug delivery technology
EP2670780A4 (en) Cellulose-based nanoparticles for drug delivery
SG11201501917SA (en) Composite hydrogels for delivery of biologically active materials
SG11201501954SA (en) Low molecular weight branched polyamines for delivery of biologically active materials
GB201110632D0 (en) Drug delivery formulations
HK1255382A1 (en) Preparation of lipid nanoparticles
IL227591A0 (en) Nanoparticles based for dermal and systemic delivery of drugs
GB201101122D0 (en) Nanoparticles for dermal and systemic delivery of drugs
GB201015091D0 (en) Enhanced delivery of sirna